The document discusses a human blood-brain barrier (BBB) model characterized with primary human cells and engineered hydrogels to mimic the in vivo extracellular matrix. It highlights the importance of stiffness, customizable features, and high-throughput screening capabilities. Additionally, it details the optimization of protocols for assessing drug permeability and toxic assays in the BBB model.